版本:
中国

BRIEF-Tenax meets with FDA to discuss positive mortality data and potential levosimendan NDA submission

May 16 Tenax Therapeutics Inc

* Tenax meets with FDA to discuss positive mortality data and potential levosimendan NDA submission

* Tenax Therapeutics - Analysis of pre-specified LEVO-CTS subgroup of isolated CABG surgery patients indicates a 73% reduction in 90-day all-cause mortality

* Tenax Therapeutics - Mortality reduction in LEVO-CTS isolated CABG patients is consistent with study hypothesis and data from previously published trials

* Tenax Therapeutics Inc - FDA requested submission of additional information from published cross study analyses that were presented during meeting

* Tenax - Met with FDA on May 10 to review additional data analyses from phase 3 LEVO-CTS clinical study of levosimendan in cardiac surgery patients at LCOS risk Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐